{"hands_on_practices": [{"introduction": "A cornerstone of analyzing data from Single Ascending Dose (SAD) studies is the ability to quantify total drug exposure from plasma concentration-time measurements. This practice focuses on Noncompartmental Analysis (NCA), a robust method for calculating the Area Under the Curve ($AUC$) without assuming a specific physiological model. By working through this exercise [@problem_id:5061636], you will master the application of the trapezoidal rule and the critical process of extrapolating to infinity, essential skills for interpreting the results of first-in-human trials.", "problem": "A first-in-human Single Ascending Dose (SAD) part of a translational medicine study evaluates the pharmacokinetics of a new small-molecule oral agent after a single dose. Plasma concentrations are measured at multiple post-dose times. Use Noncompartmental Analysis (NCA) to compute the area under the plasma concentration-time curve from time zero extrapolated to infinity, denoted $AUC_{0-\\infty}$. You must derive any working expressions you use from foundational definitions. Conclude whether the fraction of $AUC_{0-\\infty}$ obtained by extrapolation beyond the last measurable concentration is acceptable based on the suitability of the terminal phase.\n\nFoundational bases you may assume:\n- $AUC$ is defined as the integral of concentration over time, $AUC = \\int C(t)\\,dt$.\n- For NCA, the observed $AUC$ up to the last quantifiable time is approximated by a trapezoidal summation consistent with the data’s monotonicity, and the terminal tail beyond the last time is estimated using the terminal elimination rate constant under an exponential terminal phase.\n\nData: time in hours ($t$, in $\\mathrm{h}$) and plasma concentration ($C$, in $\\mathrm{ng\\cdot mL^{-1}}$) are given as ordered pairs $(t, C)$:\n- $(\\,0,\\;0\\,)$\n- $(\\,0.5,\\;4\\,)$\n- $(\\,1,\\;8\\,)$\n- $(\\,2,\\;16\\,)$\n- $(\\,4,\\;32\\,)$\n- $(\\,6,\\;32\\,)$\n- $(\\,12,\\;16\\,)$\n- $(\\,24,\\;8\\,)$\n- $(\\,36,\\;4\\,)$\n- $(\\,48,\\;2\\,)$\n\nTasks:\n1. Using the linear-up/log-down trapezoidal approach derived from first principles, compute $AUC_{0-t_{\\text{last}}}$ up to $t_{\\text{last}} = 48\\,\\mathrm{h}$. Then, identify an appropriate terminal log-linear phase, estimate the terminal elimination rate constant $\\lambda_{z}$ from the selected log-linear data, and compute the extrapolated tail area $AUC_{\\text{extra}} = \\int_{t_{\\text{last}}}^{\\infty} C(t)\\,dt$.\n2. Report $AUC_{0-\\infty} = AUC_{0-t_{\\text{last}}} + AUC_{\\text{extra}}$.\n3. Justify the terminal phase selection and evaluate whether the fraction extrapolated $AUC_{\\text{extra}}/AUC_{0-\\infty}$ meets common rigor for SAD/MAD pharmacokinetic characterization, using the data’s terminal slope characteristics and quantifiable last concentration.\n\nExpress the final $AUC_{0-\\infty}$ in $\\mathrm{ng\\cdot h\\cdot mL^{-1}}$ and round your answer to $4$ significant figures. Your final numerical answer must be a single real value. Do not include any units in your final boxed answer.", "solution": "The problem requires the calculation of the total area under the plasma concentration-time curve from time zero to infinity, $AUC_{0-\\infty}$, using noncompartmental analysis (NCA). This involves two primary components: the area calculated from the observed data up to the last measurement time, $AUC_{0-t_{\\text{last}}}$, and the extrapolated area from the last measurement time to infinity, $AUC_{\\text{extra}}$.\n\nFirst, we calculate $AUC_{0-t_{\\text{last}}}$. The problem specifies the use of the linear-up/log-down trapezoidal method. This method approximates the area for each time interval $(t_i, t_{i+1})$ based on the change in concentration ($C_i, C_{i+1}$).\n\nThe area of a single trapezoid between time points $t_i$ and $t_{i+1}$ is given by the integral $AUC_{i, i+1} = \\int_{t_i}^{t_{i+1}} C(t) \\,dt$.\n\nFor intervals where concentration is non-decreasing ($C_{i+1} \\geq C_i$), we approximate $C(t)$ with a linear function connecting $(t_i, C_i)$ and $(t_{i+1}, C_{i+1})$. The integral evaluates to the area of a linear trapezoid:\n$$AUC_{i, i+1} = (t_{i+1} - t_i) \\frac{C_i + C_{i+1}}{2}$$\nFor intervals where concentration is decreasing ($C_{i+1}  C_i$), we assume an exponential decline. The concentration is modeled as $C(t) = C_i \\exp(-k(t-t_i))$. The integral evaluates to the area under this exponential curve, which is the logarithmic trapezoid formula:\n$$AUC_{i, i+1} = (t_{i+1} - t_i) \\frac{C_i - C_{i+1}}{\\ln(C_i / C_{i+1})}$$\nWe now apply these formulas to the provided data points $(t, C)$: $(0, 0), (0.5, 4), (1, 8), (2, 16), (4, 32), (6, 32), (12, 16), (24, 8), (36, 4), (48, 2)$. The last measurable time point is $t_{\\text{last}} = 48\\,\\mathrm{h}$.\n\n1.  Interval $t=0$ to $t=0.5\\,\\mathrm{h}$: $C$ increases from $0$ to $4\\,\\mathrm{ng \\cdot mL^{-1}}$. Linear rule applies.\n    $AUC_{0-0.5} = (0.5 - 0) \\frac{0 + 4}{2} = 1.0\\,\\mathrm{ng \\cdot h \\cdot mL^{-1}}$\n2.  Interval $t=0.5$ to $t=1\\,\\mathrm{h}$: $C$ increases from $4$ to $8\\,\\mathrm{ng \\cdot mL^{-1}}$. Linear rule.\n    $AUC_{0.5-1} = (1 - 0.5) \\frac{4 + 8}{2} = 3.0\\,\\mathrm{ng \\cdot h \\cdot mL^{-1}}$\n3.  Interval $t=1$ to $t=2\\,\\mathrm{h}$: $C$ increases from $8$ to $16\\,\\mathrm{ng \\cdot mL^{-1}}$. Linear rule.\n    $AUC_{1-2} = (2 - 1) \\frac{8 + 16}{2} = 12.0\\,\\mathrm{ng \\cdot h \\cdot mL^{-1}}$\n4.  Interval $t=2$ to $t=4\\,\\mathrm{h}$: $C$ increases from $16$ to $32\\,\\mathrm{ng \\cdot mL^{-1}}$. Linear rule.\n    $AUC_{2-4} = (4 - 2) \\frac{16 + 32}{2} = 48.0\\,\\mathrm{ng \\cdot h \\cdot mL^{-1}}$\n5.  Interval $t=4$ to $t=6\\,\\mathrm{h}$: $C$ is constant at $32\\,\\mathrm{ng \\cdot mL^{-1}}$. Linear rule applies ($C_{i+1} \\geq C_i$).\n    $AUC_{4-6} = (6 - 4) \\frac{32 + 32}{2} = 64.0\\,\\mathrm{ng \\cdot h \\cdot mL^{-1}}$\n6.  Interval $t=6$ to $t=12\\,\\mathrm{h}$: $C$ decreases from $32$ to $16\\,\\mathrm{ng \\cdot mL^{-1}}$. Logarithmic rule.\n    $AUC_{6-12} = (12 - 6) \\frac{32 - 16}{\\ln(32/16)} = \\frac{6 \\times 16}{\\ln(2)} = \\frac{96}{\\ln(2)}\\,\\mathrm{ng \\cdot h \\cdot mL^{-1}}$\n7.  Interval $t=12$ to $t=24\\,\\mathrm{h}$: $C$ decreases from $16$ to $8\\,\\mathrm{ng \\cdot mL^{-1}}$. Logarithmic rule.\n    $AUC_{12-24} = (24 - 12) \\frac{16 - 8}{\\ln(16/8)} = \\frac{12 \\times 8}{\\ln(2)} = \\frac{96}{\\ln(2)}\\,\\mathrm{ng \\cdot h \\cdot mL^{-1}}$\n8.  Interval $t=24$ to $t=36\\,\\mathrm{h}$: $C$ decreases from $8$ to $4\\,\\mathrm{ng \\cdot mL^{-1}}$. Logarithmic rule.\n    $AUC_{24-36} = (36 - 24) \\frac{8 - 4}{\\ln(8/4)} = \\frac{12 \\times 4}{\\ln(2)} = \\frac{48}{\\ln(2)}\\,\\mathrm{ng \\cdot h \\cdot mL^{-1}}$\n9.  Interval $t=36$ to $t=48\\,\\mathrm{h}$: $C$ decreases from $4$ to $2\\,\\mathrm{ng \\cdot mL^{-1}}$. Logarithmic rule.\n    $AUC_{36-48} = (48 - 36) \\frac{4 - 2}{\\ln(4/2)} = \\frac{12 \\times 2}{\\ln(2)} = \\frac{24}{\\ln(2)}\\,\\mathrm{ng \\cdot h \\cdot mL^{-1}}$\n\nSumming these partial areas gives $AUC_{0-t_{\\text{last}}}$:\n$$AUC_{0-48} = (1 + 3 + 12 + 48 + 64) + \\frac{96+96+48+24}{\\ln(2)}$$\n$$AUC_{0-48} = 128 + \\frac{264}{\\ln(2)}\\,\\mathrm{ng \\cdot h \\cdot mL^{-1}}$$\n\nNext, we identify the terminal log-linear phase to estimate the terminal elimination rate constant, $\\lambda_z$. We plot the natural logarithm of concentration, $\\ln(C)$, versus time $t$ for the final data points:\n- $(t=12, C=16) \\implies \\ln(C) = \\ln(16) = 4\\ln(2)$\n- $(t=24, C=8) \\implies \\ln(C) = \\ln(8) = 3\\ln(2)$\n- $(t=36, C=4) \\implies \\ln(C) = \\ln(4) = 2\\ln(2)$\n- $(t=48, C=2) \\implies \\ln(C) = \\ln(2)$\nThese four points form a perfect straight line on a semi-log plot. The terminal elimination rate constant $\\lambda_z$ is the negative of the slope of this line. The slope, $m$, is:\n$$m = \\frac{\\Delta(\\ln(C))}{\\Delta t} = \\frac{\\ln(2) - \\ln(16)}{48 - 12} = \\frac{\\ln(2/16)}{36} = \\frac{\\ln(1/8)}{36} = \\frac{-3\\ln(2)}{36} = -\\frac{\\ln(2)}{12}$$\nTherefore, $\\lambda_z = -m = \\frac{\\ln(2)}{12}\\,\\mathrm{h}^{-1}$.\n\nNow we compute the extrapolated area, $AUC_{\\text{extra}}$. This is the area from $t_{\\text{last}}$ to infinity, assuming concentration decays exponentially with rate constant $\\lambda_z$ from the last measured concentration, $C_{\\text{last}}$.\n$$AUC_{\\text{extra}} = \\int_{t_{\\text{last}}}^{\\infty} C(t) \\,dt = \\int_{t_{\\text{last}}}^{\\infty} C_{\\text{last}} \\exp(-\\lambda_z(t-t_{\\text{last}})) \\,dt$$\n$$AUC_{\\text{extra}} = C_{\\text{last}} \\left[ -\\frac{1}{\\lambda_z} \\exp(-\\lambda_z(t-t_{\\text{last}})) \\right]_{t_{\\text{last}}}^{\\infty}$$\n$$AUC_{\\text{extra}} = C_{\\text{last}} \\left( 0 - \\left( -\\frac{1}{\\lambda_z} \\exp(0) \\right) \\right) = \\frac{C_{\\text{last}}}{\\lambda_z}$$\nUsing $t_{\\text{last}} = 48\\,\\mathrm{h}$, $C_{\\text{last}} = 2\\,\\mathrm{ng \\cdot mL^{-1}}$, and $\\lambda_z = \\frac{\\ln(2)}{12}\\,\\mathrm{h}^{-1}$:\n$$AUC_{\\text{extra}} = \\frac{2}{\\frac{\\ln(2)}{12}} = \\frac{24}{\\ln(2)}\\,\\mathrm{ng \\cdot h \\cdot mL^{-1}}$$\n\nThe total area under the curve, $AUC_{0-\\infty}$, is the sum of the observed and extrapolated areas:\n$$AUC_{0-\\infty} = AUC_{0-t_{\\text{last}}} + AUC_{\\text{extra}} = \\left( 128 + \\frac{264}{\\ln(2)} \\right) + \\frac{24}{\\ln(2)}$$\n$$AUC_{0-\\infty} = 128 + \\frac{288}{\\ln(2)}\\,\\mathrm{ng \\cdot h \\cdot mL^{-1}}$$\n\nTo obtain a numerical value, we use $\\ln(2) \\approx 0.693147$:\n$$AUC_{0-\\infty} \\approx 128 + \\frac{288}{0.693147} \\approx 128 + 415.4955 = 543.4955\\,\\mathrm{ng \\cdot h \\cdot mL^{-1}}$$\nRounding to $4$ significant figures, $AUC_{0-\\infty} = 543.5\\,\\mathrm{ng \\cdot h \\cdot mL^{-1}}$.\n\nFinally, we evaluate the suitability of the terminal phase and the reliability of the extrapolation. The fraction of AUC obtained by extrapolation is:\n$$\\%AUC_{\\text{extra}} = \\frac{AUC_{\\text{extra}}}{AUC_{0-\\infty}} \\times 100\\% = \\frac{24/\\ln(2)}{128 + 288/\\ln(2)} \\times 100\\%$$\nNumerically, this is $\\frac{34.631}{543.496} \\times 100\\% \\approx 6.37\\%$.\n\nThe selection of the terminal phase from $t=12\\,\\mathrm{h}$ to $t=48\\,\\mathrm{h}$ is strongly justified:\n1.  It includes four data points, which is more than the minimum of three typically required.\n2.  The data points exhibit an exceptionally strong log-linear relationship, as demonstrated by their perfect fit to a straight line on a semi-log plot (implying a coefficient of determination $R^2=1.0$).\n3.  The time period over which the terminal phase is defined ($36\\,\\mathrm{h}$) covers three terminal half-lives ($t_{1/2} = \\ln(2)/\\lambda_z = 12\\,\\mathrm{h}$). This long duration provides high confidence in the estimate of $\\lambda_z$.\n\nThe percentage of the total AUC that is extrapolated is approximately $6.4\\%$. Standard practice in pharmacokinetics considers an extrapolated area of less than $20\\%$ to be acceptable for a reliable estimation of $AUC_{0-\\infty}$. Since $6.4\\%$ is well below this threshold, the characterization of the terminal phase is considered robust, and the resulting $AUC_{0-\\infty}$ is a reliable parameter estimate for this SAD study.\n\nFinal numerical calculation rounded to four significant figures:\n$AUC_{0-\\infty} = 543.4955 \\approx 543.5$.", "answer": "$$\\boxed{543.5}$$", "id": "5061636"}, {"introduction": "Once total drug exposure can be quantified, a key objective in early clinical development is to determine a drug's absolute oral bioavailability ($F$). This parameter measures the fraction of an orally administered dose that reaches systemic circulation and is crucial for bridging between intravenous and oral formulations. This exercise [@problem_id:5061637] simulates a crossover study design, challenging you to integrate AUC calculations from two different routes of administration to derive $F$ from first principles and consider the potential sources of error in such comparisons.", "problem": "A first-in-human Single Ascending Dose (SAD) crossover study is conducted to estimate the absolute oral bioavailability of a new small-molecule drug under linear, time-invariant pharmacokinetics. In Period A, each subject receives an oral immediate-release dose of $60$ mg after an overnight fast. In Period B (separated by an adequate washout), each subject receives an Intravenous (IV) microdose of $6$ mg. Plasma concentrations are quantified with a validated assay, and Area Under the Concentration–Time Curve (AUC) values are computed up to the last quantifiable concentration using the linear-up/log-down trapezoidal rule. The measured partial AUCs and the last two terminal concentrations for each period are summarized below (pooled across subjects for the purpose of this calculation):\n\n- Oral period: $AUC_{0-24} = 4200$ $\\text{ng}\\cdot\\text{h}/\\text{mL}$; last two measurable concentrations on the terminal log-linear phase are $C(18\\,\\text{h}) = 35$ $\\text{ng}/\\text{mL}$ and $C(24\\,\\text{h}) = 20$ $\\text{ng}/\\text{mL}$.\n- IV period: $AUC_{0-12} = 1800$ $\\text{ng}\\cdot\\text{h}/\\text{mL}$; last two measurable concentrations on the terminal log-linear phase are $C(8\\,\\text{h}) = 60$ $\\text{ng}/\\text{mL}$ and $C(12\\,\\text{h}) = 30$ $\\text{ng}/\\text{mL}$.\n\nAssume the following foundational conditions, reflecting the core definitions and well-tested relationships of linear pharmacokinetics relevant to translational medicine and Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) studies:\n\n- First-order elimination with a log-linear terminal phase and eventual complete absorption after oral administration.\n- Time-invariant and route-invariant clearance in the absence of drug–drug interactions or disease progression.\n- No saturation of absorption, distribution, metabolism, or excretion over the studied dose range.\n\nTasks:\n\n1. Starting from the core definitions that relate dose, clearance, and exposure for extravascular and IV administration in a linear system, derive an expression for the absolute oral bioavailability $F$ in terms of $AUC$ extrapolated to infinity for each route and the administered doses. Do not assume or quote any target formulas; derive the expression from first principles.\n2. Using only the data provided and first-order terminal kinetics, estimate the terminal elimination rate constant for each route from the last two terminal concentrations, and use this to extrapolate each partial $AUC$ to $AUC_{\\infty}$.\n3. Evaluate your derived expression for $F$ using $AUC_{\\infty}$ values for the oral and IV periods and the administered doses.\n\nExpress the final bioavailability as a pure decimal (unitless). Round your final answer to four significant figures. In your reasoning, briefly identify the dominant sources of bias or error that can affect the accuracy of $F$ estimation in SAD crossover designs, focusing on those that would distort the ratio of dose-normalized $AUC$ values. Your final submitted answer must be only the numerical value for $F$ as specified above.", "solution": "#### Task 1: Derivation of the Expression for Absolute Bioavailability ($F$)\nThe derivation begins from the definition of clearance ($CL$), which is the proportionality constant relating the rate of drug elimination from the body to its concentration in plasma, $C(t)$.\n$$ \\text{Rate of Elimination} = CL \\cdot C(t) $$\nThe total amount of drug eliminated from the body over all time is the integral of this rate from time zero to infinity.\n$$ \\text{Total Amount Eliminated} = \\int_{0}^{\\infty} CL \\cdot C(t) dt $$\nAssuming clearance ($CL$) is constant (time-invariant), it can be moved outside the integral.\n$$ \\text{Total Amount Eliminated} = CL \\cdot \\int_{0}^{\\infty} C(t) dt $$\nThe integral term is the definition of the total Area Under the Concentration-Time Curve, $AUC_{0-\\infty}$.\n$$ \\text{Total Amount Eliminated} = CL \\cdot AUC_{0-\\infty} $$\nThis fundamental relationship can be applied to both intravenous (IV) and extravascular (e.g., oral) administration routes.\n\nFor an intravenous bolus dose, $D_{IV}$, the entire dose enters the systemic circulation. Therefore, the total amount of drug that will be eliminated by the body must equal $D_{IV}$.\n$$ D_{IV} = CL \\cdot AUC_{IV, 0-\\infty} \\quad (1) $$\n\nFor an oral dose, $D_{oral}$, only a fraction, $F$ (the absolute bioavailability), of the administered dose reaches the systemic circulation due to incomplete absorption and/or first-pass metabolism. The total amount of drug entering the systemic circulation is $F \\cdot D_{oral}$. This is the amount that is available to be eliminated by the body.\n$$ F \\cdot D_{oral} = CL \\cdot AUC_{oral, 0-\\infty} \\quad (2) $$\nThe problem states to assume that clearance is route-invariant, meaning $CL$ is the same for both the oral and IV periods. We can therefore solve for $CL$ in equation (1) and substitute it into equation (2).\nFrom (1): $CL = \\frac{D_{IV}}{AUC_{IV, 0-\\infty}}$.\nSubstituting into (2):\n$$ F \\cdot D_{oral} = \\left(\\frac{D_{IV}}{AUC_{IV, 0-\\infty}}\\right) \\cdot AUC_{oral, 0-\\infty} $$\nRearranging to solve for the absolute bioavailability, $F$:\n$$ F = \\frac{D_{IV}}{D_{oral}} \\cdot \\frac{AUC_{oral, 0-\\infty}}{AUC_{IV, 0-\\infty}} $$\nThis expression can also be written in terms of dose-normalized AUCs, which makes the definition of F as a ratio of exposures explicit:\n$$ F = \\frac{AUC_{oral, 0-\\infty} / D_{oral}}{AUC_{IV, 0-\\infty} / D_{IV}} $$\nThis completes the derivation from first principles.\n\n#### Task 2: Estimation of Terminal Elimination Rate Constants and Extrapolation of AUC\nThe terminal elimination rate constant, $k_{el}$, is estimated from the slope of the log-linear terminal phase. Given two concentrations, $C_1$ at time $t_1$ and $C_2$ at time $t_2$, on this phase, $k_{el}$ is calculated as:\n$$ k_{el} = \\frac{\\ln(C_1) - \\ln(C_2)}{t_2 - t_1} $$\nThe total AUC extrapolated to infinity, $AUC_{0-\\infty}$, is the sum of the partial AUC measured up to the last quantifiable concentration at time $t_{last}$, $AUC_{0-t_{last}}$, and the extrapolated area from $t_{last}$ to infinity. This extrapolated area is calculated as the last quantifiable concentration, $C_{last}$, divided by the terminal elimination rate constant, $k_{el}$.\n$$ AUC_{0-\\infty} = AUC_{0-t_{last}} + \\frac{C_{last}}{k_{el}} $$\n\n**Oral Period Calculation:**\n- Data: $AUC_{0-24} = 4200$ $\\text{ng}\\cdot\\text{h}/\\text{mL}$. $C_1 = 35$ $\\text{ng}/\\text{mL}$ at $t_1 = 18$ h; $C_2 = 20$ $\\text{ng}/\\text{mL}$ at $t_2 = 24$ h. $C_{last} = 20$ $\\text{ng}/\\text{mL}$ at $t_{last}=24$ h.\n- Estimate $k_{el, oral}$:\n$$ k_{el, oral} = \\frac{\\ln(35) - \\ln(20)}{24\\,\\text{h} - 18\\,\\text{h}} = \\frac{\\ln(1.75)}{6} \\, \\text{h}^{-1} $$\n- Extrapolate $AUC_{oral, 0-\\infty}$:\n$$ AUC_{oral, 0-\\infty} = 4200 + \\frac{20}{k_{el, oral}} = 4200 + \\frac{20}{\\frac{\\ln(1.75)}{6}} = 4200 + \\frac{120}{\\ln(1.75)} \\, \\text{ng}\\cdot\\text{h}/\\text{mL} $$\n\n**Intravenous Period Calculation:**\n- Data: $AUC_{0-12} = 1800$ $\\text{ng}\\cdot\\text{h}/\\text{mL}$. $C_1 = 60$ $\\text{ng}/\\text{mL}$ at $t_1 = 8$ h; $C_2 = 30$ $\\text{ng}/\\text{mL}$ at $t_2 = 12$ h. $C_{last} = 30$ $\\text{ng}/\\text{mL}$ at $t_{last}=12$ h.\n- Estimate $k_{el, IV}$:\n$$ k_{el, IV} = \\frac{\\ln(60) - \\ln(30)}{12\\,\\text{h} - 8\\,\\text{h}} = \\frac{\\ln(2)}{4} \\, \\text{h}^{-1} $$\n- Extrapolate $AUC_{IV, 0-\\infty}$:\n$$ AUC_{IV, 0-\\infty} = 1800 + \\frac{30}{k_{el, IV}} = 1800 + \\frac{30}{\\frac{\\ln(2)}{4}} = 1800 + \\frac{120}{\\ln(2)} \\, \\text{ng}\\cdot\\text{h}/\\text{mL} $$\n\n#### Task 3: Evaluation of $F$ and Discussion of Biases\nUsing the derived expression for $F$ and the extrapolated AUC values:\n$$ F = \\frac{D_{IV}}{D_{oral}} \\cdot \\frac{AUC_{oral, 0-\\infty}}{AUC_{IV, 0-\\infty}} $$\nSubstitute the given doses and the calculated AUC expressions:\n$$ F = \\frac{6\\,\\text{mg}}{60\\,\\text{mg}} \\cdot \\frac{4200 + \\frac{120}{\\ln(1.75)}}{1800 + \\frac{120}{\\ln(2)}} $$\n$$ F = 0.1 \\cdot \\frac{4200 + \\frac{120}{0.5596157...}}{1800 + \\frac{120}{0.6931471...}} $$\n$$ F = 0.1 \\cdot \\frac{4200 + 214.4316...}{1800 + 173.1233...} $$\n$$ F = 0.1 \\cdot \\frac{4414.4316...}{1973.1233...} $$\n$$ F \\approx 0.1 \\cdot 2.237263... $$\n$$ F \\approx 0.2237263... $$\nRounding to four significant figures, the absolute oral bioavailability is $F = 0.2237$.\n\nThe dominant sources of bias or error that can affect the accuracy of this estimation primarily relate to violations of the foundational assumptions:\n1.  **Non-linearity/Dose-dependence**: The calculation assumes linear pharmacokinetics, meaning clearance ($CL$) is constant across the dose range. Here, a $60$ mg oral dose is compared to a $6$ mg IV microdose. If metabolic pathways become saturated at the higher concentrations resulting from the oral dose, clearance would decrease. This would lead to a disproportionately larger $AUC_{oral}$, causing an overestimation of $F$.\n2.  **Error in AUC Extrapolation**: The accuracy of $F$ depends on the accuracy of $AUC_{0-\\infty}$. The extrapolated portion ($AUC_{t_{last}-\\infty}$) relies on a precise estimate of $k_{el}$, which can be highly sensitive to assay error at low concentrations and the subjective selection of points for the terminal phase regression. A large extrapolated area (typically $20\\%$ of the total AUC) is considered a source of significant uncertainty.\n3.  **Route-dependent Clearance**: While assumed to be invariant, clearance could differ between routes if the drug has high first-pass extraction in the gut wall or liver. The IV microdose may not be sufficient to accurately characterize the clearance relevant to the higher-concentration portal vein exposure after an oral dose, potentially biasing the $AUC$ ratio.", "answer": "$$\\boxed{0.2237}$$", "id": "5061637"}, {"introduction": "A critical outcome of SAD and preclinical studies is the ability to inform the safe design of subsequent Multiple Ascending Dose (MAD) cohorts. This forward-looking practice demonstrates how to translate nonclinical toxicology findings, such as the No-Observed-Adverse-Effect-Level (NOAEL), into actionable safety margins for human trials. In this exercise [@problem_id:5061485], you will use pharmacokinetic modeling to predict steady-state exposures and determine the maximum allowable dose that respects predefined safety boundaries, a core task in clinical trial planning.", "problem": "A first-in-human program for a small-molecule therapeutic is transitioning from Single Ascending Dose (SAD) to Multiple Ascending Dose (MAD). The study team will escalate to a once-daily oral regimen and must preserve predefined safety margins relative to the Non-Observed Adverse Effect Level (NOAEL). The most sensitive nonclinical toxicology species exhibited a NOAEL with a peak plasma concentration of $C_{\\max,\\text{NOAEL}} = 6$ and a $24$-hour area under the concentration–time curve of $AUC_{0-24,\\text{NOAEL}} = 150$. The translational pharmacokinetic assumptions for humans are: linear one-compartment disposition with first-order elimination, oral bioavailability $F = 0.60$, clearance $CL = 12$, volume of distribution $V = 100$, and a dosing interval $\\tau = 24$. Assume absorption is rapid relative to elimination so that the peak occurs near the time of dosing. The predefined exposure-multiple margins to NOAEL to be maintained in the MAD cohort are $m_{C} = 10$ for peak concentration and $m_{A} = 10$ for $24$-hour exposure. Construct the exposure multiples to NOAEL using model-based predicted human steady-state peak concentration and $24$-hour exposure under these assumptions, then impose the margin constraints to determine the maximum allowable daily oral dose that satisfies both margins simultaneously. Express the final dose in milligrams (mg) and round your answer to three significant figures.", "solution": "The objective is to determine the maximum allowable daily oral dose, which we will denote as $D$, for a multiple ascending dose (MAD) study. This dose must satisfy two safety margin constraints simultaneously, based on nonclinical toxicology data and predicted human pharmacokinetics (PK).\n\nThe problem provides the following givens from the nonclinical toxicology study:\n- Peak plasma concentration at the Non-Observed Adverse Effect Level: $C_{\\max,\\text{NOAEL}} = 6$\n- $24$-hour area under the curve at the Non-Observed Adverse Effect Level: $AUC_{0-24,\\text{NOAEL}} = 150$\n\nThe human PK parameters and study design are:\n- Oral bioavailability: $F = 0.60$\n- Clearance: $CL = 12$\n- Volume of distribution: $V = 100$\n- Dosing interval: $\\tau = 24$\n- The model is a linear one-compartment disposition with first-order elimination.\n- Absorption is assumed to be rapid, approximating an intravenous (IV) bolus for peak concentration calculations.\n\nThe safety margins to be maintained are:\n- Margin for peak concentration: $m_{C} = 10$\n- Margin for $24$-hour exposure (AUC): $m_{A} = 10$\n\nThe safety constraints require that the predicted human steady-state exposure does not exceed the NOAEL exposure divided by the respective safety margin.\n\nConstraint 1: Peak Concentration ($C_{\\max}$)\nThe predicted human steady-state peak concentration, $C_{\\max, ss}$, must satisfy:\n$$C_{\\max, ss} \\le \\frac{C_{\\max, \\text{NOAEL}}}{m_{C}}$$\n\nConstraint 2: Area Under the Curve (AUC)\nThe predicted human steady-state area under the concentration-time curve over the dosing interval, $AUC_{0-\\tau, ss}$, must satisfy:\n$$AUC_{0-\\tau, ss} \\le \\frac{AUC_{0-24, \\text{NOAEL}}}{m_{A}}$$\nSince the dosing interval $\\tau = 24$ hours, this simplifies to $AUC_{0-24, ss}$.\n\nFirst, we determine the first-order elimination rate constant, $k_e$, from the provided clearance and volume of distribution:\n$$k_e = \\frac{CL}{V} = \\frac{12}{100} = 0.12 \\text{ h}^{-1}$$\n\nNext, we write the expressions for the human steady-state PK parameters as a function of the oral dose $D$.\n\nFor AUC, the steady-state exposure over one dosing interval is given by:\n$$AUC_{0-\\tau, ss} = \\frac{F \\cdot D}{CL}$$\n\nFor $C_{\\max}$, using the assumption of rapid absorption, we model the peak concentration as if the bioavailable dose ($F \\cdot D$) were administered as an IV bolus. The peak concentration at steady-state for a multiple IV bolus regimen is:\n$$C_{\\max, ss} = \\frac{F \\cdot D}{V} \\cdot \\frac{1}{1 - \\exp(-k_e \\tau)}$$\nThe term $\\frac{1}{1 - \\exp(-k_e \\tau)}$ is the accumulation ratio.\n\nNow, we can substitute these expressions into the safety constraints to find the maximum dose allowed by each.\n\nFrom the AUC constraint (Constraint 2):\n$$\\frac{F \\cdot D}{CL} \\le \\frac{AUC_{0-24, \\text{NOAEL}}}{m_{A}}$$\nSolving for the dose $D$, we find the maximum dose allowed by the AUC constraint, $D_A$:\n$$D \\le \\frac{AUC_{0-24, \\text{NOAEL}} \\cdot CL}{m_A \\cdot F}$$\n$$D_A = \\frac{150 \\cdot 12}{10 \\cdot 0.60} = \\frac{1800}{6} = 300$$\n\nFrom the $C_{\\max}$ constraint (Constraint 1):\n$$\\frac{F \\cdot D}{V} \\cdot \\frac{1}{1 - \\exp(-k_e \\tau)} \\le \\frac{C_{\\max, \\text{NOAEL}}}{m_{C}}$$\nSolving for the dose $D$, we find the maximum dose allowed by the $C_{\\max}$ constraint, $D_C$:\n$$D \\le \\frac{C_{\\max, \\text{NOAEL}} \\cdot V \\cdot (1 - \\exp(-k_e \\tau))}{m_{C} \\cdot F}$$\nFirst, we calculate the value of the exponent $k_e \\tau$:\n$$k_e \\tau = 0.12 \\text{ h}^{-1} \\times 24 \\text{ h} = 2.88$$\nNow, we substitute the values into the inequality for $D_C$:\n$$D_C = \\frac{6 \\cdot 100 \\cdot (1 - \\exp(-2.88))}{10 \\cdot 0.60} = \\frac{600 \\cdot (1 - \\exp(-2.88))}{6} = 100 \\cdot (1 - \\exp(-2.88))$$\nUsing $\\exp(-2.88) \\approx 0.056134$, we get:\n$$D_C \\approx 100 \\cdot (1 - 0.056134) = 100 \\cdot 0.943866 = 94.3866$$\n\nWe have two upper limits for the dose:\n- From the AUC constraint: $D \\le 300$ mg\n- From the $C_{\\max}$ constraint: $D \\le 94.3866$ mg\n\nTo satisfy both constraints simultaneously, the dose must be less than or equal to the minimum of these two values.\n$$D_{\\text{max}} = \\min(D_A, D_C) = \\min(300, 94.3866) = 94.3866 \\text{ mg}$$\n\nThe problem requires the final answer to be rounded to three significant figures.\n$$D_{\\text{max}} \\approx 94.4 \\text{ mg}$$\nThus, the maximum allowable daily oral dose is $94.4$ mg.", "answer": "$$\\boxed{94.4}$$", "id": "5061485"}]}